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Summary 
The effect of the phosphodiesterase inhibitor isobutyl-methylxanthine 
(IBMX), salbutamol and sodium nitroprusside was evaluated regarding 
PGF-.2 and LTB4 release and cAMP and cGMP level in human alveolar 
macrophages obtained from controls and COPD patients. Basal levels per 
five million control- respectively COPD alveolar macrophages: cAMP 1.2 
and 1.0 pmole; cGMP 8.4 and 9.1 fmole; PGE. 2 120 and 63 pg and LTB 4 
19.2 and 14.8 pg. In both populations IBMX increased cAMP level by 
55-93% and salbutamol+IBMX by 285-252%. Except for the 61% rise in 
LTB, release by salbutamol+lBMX the drugs hardly affected PGE 2 and 
LTB 4 release from control macrophages. In COPD alveolar macrophages, 
however, IBMX and IBMX+salbutamol largely reduced PGE 2 release (63 
vs 11 pg per l0 s cells) but less efficiently increased LTB 4. In both 
macrophage populations sodium nitroprusside (SNP) substantially increa- 
sod (3-4 fold) cGMP level but did not affect eicosanoid production. 
Present results indicate that drugs which enhance cAMP level decrease 
PGF~ release from COPD macrophages and stimulate the release of LTB 4 
a chemotactic mediator involved in bronchial inflammatory eactions. 
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Airway inflammation is a characteristic feature of both asthma and chronic obstructive 
pulmonary diseases (COPD) resulting from largely unknown pathophysiological events (1). 
Alveolar macrophages (AM) modulate the activity of other cells via the release of cytokines, 
prostaglandins, leukotrienes and PAF (2,3). The released eicosanoids, notably LTB 4 (4-5) and 
PGE 2 (6) may affect via feedback mechanism(s) macrophage activity itself (7-9) or the activity 
of other cells (10). LTB 4 for instance is chemotactic for mast cells (11), eosinophils (12) and 
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neutrophils (13). Stimulated AM from asthmatic patients release larger amounts of inflammato- 
ry mediators than AM derived from healthy subjects (14,15) though others did not confirm this 
(16). Release of lipid mediators (prostaglandins, leukotrienes and PAF) from AM may have 
important implications for the micro-environment of he bronchoalveolar compartment. 
The modulatory effects of AM depend on various factors like basal intracellular cAMP level, 
state of priming and exposure to biologically active substances. Increase in intracellular cAMP 
level generally decreases cellular activity. For instance elevation of cAMP inhibits zymosan- 
stimulated arachidonic acid release in monocytes (17) and the production of thromboxane B2 
and LTB 4 in elicited peritoneal macrophages (18). Whether in addition cGMP level is also of 
importance in the control of cellular activity is not well established. Zymosan elicits a rapid 
rise in both cAMP and cGMP formation (19) and muramyl dipeptide (20), sodium nitroprusside 
(19), and exogenous cGMP have been shown to enhance macrophage activity (20,21). Others, 
however, do not observe macrophage activation by inducers of cGMP production (19). 
The effect of bronchodilating drugs (salbutamol, sodium nitroprusside and theophylline-like 
compounds) are believed to be beneficial only. However, by changing intracellular cyclic 
nucleotide levels these drugs may in addition alter the functional activity of AM, known to be 
involved in airway inflammation. 
Materials and Methods 
Ten patients (female, age 25-40 yrs, mean age 31, all smokers, > 7 pack years) hospitalised for 
obstetric purposes were studied. None of these subjects had a history of pulmonary disorders or 
received any medication two months prior to the study. Informed consent for bronchoalveolar 
lavage (BAL) was obtained. Alveolar cells were obtained by BAL under general anaesthesia 
using a fiberoptic bronchoscope. BAL fluids containing a total of 25-85 .106 cells were 
subsequently kept on ice. 
Lung tissue was obtained from 8 smoking (> 10 pack years) COPD patients with peripheral 
carcinoma (6 male, 2 female, mean age 51 years) who had undergone thoracotomy. According 
to the criteria of the American Thoracic Society all patients were diagnosed for COPD. Patients 
receiving beta-sympathomimetics or theophylline were excluded from the study. Mean FEV~ 
was 65.7%, mean FVC was 87.3% (calculated from normal predicted value). Within 30 min 
after surgical resection tissue was immersed in ice-cold buffer. AM were recovered by in-vitro 
lavage of segments using a 20 ml syringe. 
BAL fluids were filtered through surgical gauze and centrifuged at 400g (10 min, 4°C). The 
pellet was resuspended in Gey Balanced Salt Solution (GBSS), pH 7.4 and AM were purified 
by Ficoll-Isopaque centrifugation (400g, 30 min, 4°C) and the resultant AM layer was washed 
twice. May Grtinwald Giemsa staining showed that the suspension contained approximately 
96% (control) and 86% (COPD) AM. Viability of the cells was at least 95%. Cells were not 
further purified via culturing to avoid frustrated phagocytosis eliciting cell activation. 
AM (2.10 ~ ml "1) were incubated in GBSS buffer at 370C for 60 min and drugs dissolved in 
GBSS. In some experiments cell suspensions were pre-incubated for 15 min with 10 laM 
propranolol. Incubation was stopped by centrifugation (1 min, 15,000g) and the supernatant 
was removed, freeze dried and stored at -80*C for analysis of eicosanoids. The pellet was 
resuspended in 150 lal Tris-HCl buffer (pH 7.4) and boiled for 3 min. PGE 2 and LTB 4 were 
assayed by ELISA. Detection limits for PGE 2 and LTB 4 were 3 and 1 pg/ml. Cellular cyclic 
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AMP was determined by radioimmunoassay using [3H] cAMP and an isolated binding protein 
(22). Cellular cGMP levels were determined by radioimmunoassay after acetylation (23). 
Ficoll-Isopaque (Nycomed, Oslo, Norway); IBMX (isobutyl-methylxanthine, Janssen Chimica, 
Beerse, Belgium); salbutamol, sodium nitroprusside (SNP) and BSA (Sigma, St-Louis, USA); 
propranolol (Ciba-Geigy, Basel, Switzerland); ELISA kits for PGE 2 and LTB 4 (Cayman 
Chemical, Ann Arbor, USA); [3H] cAMP and [~2sI] succinyl-cGMP tyrosine methyl ester 
(Amersham International, Amersham, UK). 
Data are expressed as means _+ s.e.mean. Statistical significance was evaluated by the Mann- 
Whitney U test. A P value < 0.05 was considered significant. 
Results 
Cellular composition of BAL and basal values of control macrophages 
Despite the use of different echniques to harvest broncholaveolar cells, cellular composition 
may be compared (24). Analysis of the cellular composition of BAL fluids showed large 
differences between controls and COPD subjects. BAL fluids of controls contained mainly AM 
(95%) and some lymphocytes (3.6%). In BAL fluids obtained from COPD patients considerable 
numbers of eosinophils (7.4%), neutrophils (14.4%) and lymphocytes (10.6%) were present. 
Basal values and effects of drugs on cyclic nucleotide levels and eicosanoid release in control 
AM are denoted in Table 1. In controls, basal cAMP and cGMP level per 106 AM was 1.4 
pmole and 8.4 fmole, reflecting a 160-fold difference in concentration. 
Levels of cyclic nucleotides and eicosanoid release in control macrophages 
In the presence of the nonselective phosphodiesterase inhibitor IBMX cAMP and cGMP levels 
rose to respectively 193% and 155% of basal level (cf. Table 1). Eicosanoid release from AM 
was only slightly though significantly affected by IBMX: per 106 AM PGE 2 release decreased 
from 120 pg to 90 pg and LTB 4 release increased from 19 to 24 pg. 
TABLE 1 
Cyclic nucleotide levels and eicosanoid release in control human AM. Data are expressed as 
mean -+ s.e.mean from 8-10 duplicate xperiments. Salb.: salbutamol; SNP: sodium nitroprussi- 
de. 
pmole cAMP/106AM fmole cGMP/106AM pg PGF_~I0~AM pg LTB4/106AM 
saline 1.4~q). 1 8.4_+ 1. I 120_+5 19.2+_4.2 
1 mM IBMX 2.7_-*0.3* 13.0-+1.7" 90-+6* 24.2-+3.5* 
1 mM IBMX + 4.0_+0.4** 13.3_+2.3 80_+3 30.4+_3.1.* 
10 taM salb. 
1 mM IBMX + 2.2_+0.3 Ns 24.3-+2.9** 98-+6 25.4+_5.1 
1 mM SNP 
* P<0.05 vs saline; ** P<0.05 vs IBMX alone; r~s non-significant vs IBMX alone. 
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TABLE 2 
Cyclic nucleotide levels and eicosanoid release in AM from COPD patients. Data are expressed 
as mean ± s.e.mean from 7-8 duplicate xperiments. Salb.: salbutamol. SNP: sodium nitroprus- 
side. 
pmole cAMP/106AM fmole cGMP/106AM pg PGEdI06AM pg LTB4/106AM 
saline 1.0-+0.1' 9.1_+1.3 63_+9 14.8-+0.5 
I mM IBMX 1.5_+0.3" 16.0__.1.9" 11-+6" 18.3_+2.0" 
1 mM IBMX + 2.5_+0.3** 13.6-+2.2 9_+3 16.2_+0.3 
10 laM salb. 
1 mM IBMX + 1.5=K).2 37.4±2.4 **'° 6_+3 17.2±0.8 
1 mM SNP 
* P<0.05 compared to control AM; * P<0.05 vs saline; ** P<0.05 vs IBMX alone; ! difference 
in effect of SNP between control-AM and COPD-AM is not significant. 
The combination of IBMX with the selective betaz-sympathomimetic salbutamol enhanced 
intracellular cAMP level more efficiently than IBMX alone (185% increase), but compared to 
IBMX PGF_q release was hardly further inhibited. Considering LTB4 release, however, salbuta- 
moI+IBMX was some two-fold more effective than IBMX alone (30.4 vs 24.2). Propranolol 
(10 p_M) completely blocked the salbutamol effects (not shown). Sodium nitroprusside (SNP) 
substantially increases cellular cGMP concentration (additional 134%) but does not affect 
cAMP content or eicosanoid release. 
Levels of cyclic nucleotides and eicosanoid release in AM from COPD patients 
Table 2 shows that untreated AM from COPD patients (refered as COPD-AM) contained less 
cAMP (-29%) and released considerable ss PGF_, 2 and LTB 4 compared to control AM (50% 
respectively 70%). The drugs IBMX and salbutamol enhanced cyclic nucleotide levels roughly 
to the same extent as in control AM. However, compared to control AM the reduction in PGE 2 
release was much larger (83% vs 21%) while LTB 4 release was slightly enhanced (24%). 
Salbutamol induced in COPD-AM a further increase in cAMP level (additional +102% 
compared to IBMX) which was not related to additional changes in PGE 2- or LTB 4 release. 
SNP showed similar responses in COPD-AM and control AM. 
Discussion 
Considering basal values for cAMP and eicosanoid release some interesting differences 
between the macrophage populations of controls and COPD patients are observed. Others 
observe about 50-fold lower amounts of eicosanoid released which may be due to the 
purification technique used (adherence/culturing) enhancing 'basal' activation state due to 
frustated phagocytosis (25). In this process eicosanoid release rises, peaks, exhausts and returns 
to some resting level. Thus it is conceivable that subsequent exposure induces maller amounts 
of released eicosanoids. Different results may also be obtained when the metabolism of a non- 
endogenous pool of tritiated arachidonic acid is determined. 
The present study compares COPD-AM with control AM from patients with no history of 
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pulmonary disorder. Both groups of AM were obtained from smokers only to allow good 
comparison as it is generally known that smoking impairs certain AM functions including 
eicosanoid production (26). In contrast o control-AM, COPD-AM are recovered from patients 
with a pulmonary environment characterized by frequent unspecified inflammations (note the 
considerable number of inflammatory cells in the BAL of COPD patients). In addition, COPD- 
AM are obtained from a rather heterogeneous group of COPD patients consuming a variety of 
drugs. So COPD-AM differ predominantly from control-AM by their origine from an inflam- 
matory environment which probably renders COPD-AM more elicited than control-AM. 
Compared to control-AM, COPD-AM show significantly lower basal level in cAMP and PGE2- 
and LTB 4 release and behave quite differently regarding induced eicosanoid release. Peritoneal 
macrophages obtained uring peritoneal inflammation likewise showed lower basal cAMP level 
and PG~ release compared to macrophages collected from patients without such complications 
(27). Drug-induced increases in cellular cAMP level was related to decreased PGE 2 and a slight 
increase in LTB 4 release. These results are only partly comparable with previous results 
obtained in activated (elicited, cultured or primed) macrophages showing that elevation of 
cAMP level inhibited both PG~ and LTB 4 release (e.g. 18). 
Interestingly, IBMX induces in the two AM populations a similar increase in cAMP level but 
affects PGE,2 release in COPD-AM to a much larger extent compared to control AM (decrease 
respectively 83 and 17%). Both macrophage populations show, however, a comparable increase 
in LTB 4 release in response to IBMX. 
We suggest hat in control AM the reduction of free arachidonic acid metabolism to PGE2 
results in a higher availability of the common substrate (free arachidonic acid) for lenkotriene 
synthesis by 5-1ipoxygenase. Simultaneous down-regulation of cyclooxygenase and enhanced 5- 
lipoxygenase activity has recently been observed by Mackenzie et al. (25) in macrophages 
exposed to calcium ionophore. The suggested inhibition of phospholipase A 2 and release of 
arachidonic acid from phospholipids by elevated cAMP (28) may only explain the decrease in 
PGE 2 release but not the change in LTB4 release. 
In both control AM and COPD-AM enhancement of cGMP level is not related to either PGE2 
or LTB4 release indicating that the cytosolic pool of cGMP is not involved in the regulation of 
eicosanoid release from AM. 
Due to their bronchodilating proporties the xanthine derivative theophylline and beta2-sympa- 
thomimetics are frequently used in the treatment of asthma nd COPD. Present results indicate 
that these drugs in addition modulate icosanoid release from AM which may have important 
implications for the micro-environment i  bronchoalveolar compartment. 
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